BusinessHemispherx Biopharma Announces Conference Call to Discuss Management Changes and Provide Corporate Update on March 30, 2016By Nasdaq OMXMar 22, 2016, 12:30 PM UTC
BusinessHemispherx Biopharma Reviews Ampligen® Data With National Institute of Neurological Disorders and Stroke (NINDS)By Nasdaq OMXMar 10, 2016, 1:30 PM UTC
BusinessHemispherx Biopharma Management Team: Reflects Company’s Aggressive Commitment to Strategies Designed to Reach Commercial Goals, Preserve Financial Capital, and Increase Stockholder ValueBy Nasdaq OMXFeb 22, 2016, 1:30 PM UTC
BusinessHemispherx Biopharma Exploring Possible Research Programs in Zika Virus Modeled on a Prior Alferon® N Clinical Trial on Closely Related Flavivirus (West Nile)By Nasdaq OMXFeb 9, 2016, 1:30 PM UTC
BusinessHemispherx Biopharma Introduces a Voluntary Stock Purchase Plan to Create Shareholder ValueBy Nasdaq OMXFeb 3, 2016, 1:30 PM UTC
BusinessHemispherx Biopharma Europe N.V./S.A. : Orphan Medicine Designation and European Medicines Agency Public Opinion Summary Published by EMA Regarding Alferon N Injection® as a Treatment of Middle East Respiratory Syndrome (MERS)By Nasdaq OMXJan 20, 2016, 1:30 PM UTC
